GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (OTCPK:EPGNF) » Definitions » Cyclically Adjusted PS Ratio

Epigenomics AG (Epigenomics AG) Cyclically Adjusted PS Ratio : 0.21 (As of Apr. 27, 2024)


View and export this data going back to . Start your Free Trial

What is Epigenomics AG Cyclically Adjusted PS Ratio?

As of today (2024-04-27), Epigenomics AG's current share price is $2.50. Epigenomics AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2023 was $12.19. Epigenomics AG's Cyclically Adjusted PS Ratio for today is 0.21.

The historical rank and industry rank for Epigenomics AG's Cyclically Adjusted PS Ratio or its related term are showing as below:

EPGNF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.11   Med: 3.05   Max: 35.99
Current: 0.12

During the past years, Epigenomics AG's highest Cyclically Adjusted PS Ratio was 35.99. The lowest was 0.11. And the median was 3.05.

EPGNF's Cyclically Adjusted PS Ratio is ranked better than
94.81% of 135 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.21 vs EPGNF: 0.12

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Epigenomics AG's adjusted revenue per share data for the three months ended in Jun. 2023 was $0.089. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $12.19 for the trailing ten years ended in Jun. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Epigenomics AG Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Epigenomics AG's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigenomics AG Cyclically Adjusted PS Ratio Chart

Epigenomics AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.18 13.00 4.20 0.93 0.60

Epigenomics AG Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 0.45 0.60 0.22 0.30

Competitive Comparison of Epigenomics AG's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, Epigenomics AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Epigenomics AG's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Epigenomics AG's Cyclically Adjusted PS Ratio falls into.



Epigenomics AG Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Epigenomics AG's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=2.50/12.19
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Epigenomics AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2023 is calculated as:

For example, Epigenomics AG's adjusted Revenue per Share data for the three months ended in Jun. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=0.089/123.1404*123.1404
=0.089

Current CPI (Jun. 2023) = 123.1404.

Epigenomics AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201309 4.046 98.983 5.033
201312 9.237 99.356 11.448
201403 5.804 99.543 7.180
201406 5.851 99.543 7.238
201409 3.894 99.823 4.804
201412 5.131 99.543 6.347
201503 3.676 99.717 4.540
201506 4.636 100.417 5.685
201509 4.266 100.417 5.231
201512 6.556 99.717 8.096
201603 2.531 100.017 3.116
201606 10.187 100.717 12.455
201609 6.783 101.017 8.269
201612 12.444 101.217 15.139
201703 1.835 101.417 2.228
201706 1.747 102.117 2.107
201709 2.559 102.717 3.068
201712 6.697 102.617 8.036
201803 2.427 102.917 2.904
201806 3.439 104.017 4.071
201809 4.045 104.718 4.757
201812 1.164 104.217 1.375
201903 1.355 104.217 1.601
201906 1.672 105.718 1.948
201909 0.808 106.018 0.938
201912 1.188 105.818 1.382
202003 0.957 105.718 1.115
202006 0.310 106.618 0.358
202009 0.875 105.818 1.018
202012 1.220 105.518 1.424
202103 0.427 107.518 0.489
202106 0.253 108.486 0.287
202109 7.639 109.435 8.596
202112 0.264 110.384 0.295
202203 0.159 113.968 0.172
202206 0.163 115.760 0.173
202209 0.176 118.818 0.182
202212 0.128 119.345 0.132
202303 0.168 122.402 0.169
202306 0.089 123.140 0.089

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Epigenomics AG  (OTCPK:EPGNF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Epigenomics AG Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Epigenomics AG (Epigenomics AG) Business Description

Traded in Other Exchanges
Address
Geneststrasse 5, Berlin, BB, DEU, 10829
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.

Epigenomics AG (Epigenomics AG) Headlines